Financial Performance - The company's revenue for the year ended December 31, 2022, was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[2] - Profit before tax for 2022 was RMB 132,294,000, down 38.7% from RMB 215,921,000 in the previous year[2] - The total comprehensive income attributable to shareholders for 2022 was RMB 136,847,000, a decline of 34.8% from RMB 210,016,000 in 2021[2] - The company's basic and diluted earnings per share for 2022 were RMB 0.1340, down from RMB 0.2049 in 2021, reflecting a decrease of 34.3%[2] - Net profit for 2022 was RMB 137,272,198, down from RMB 212,380,705 in 2021, representing a decline of 35.3%[13] - Total revenue for 2022 was $929.03 million, a decrease of 8.96% from $1,020.67 million in 2021[18] - Net profit for 2022 was $102.04 million, down 41.06% from $173.22 million in 2021[18] - Operating profit decreased to $105.92 million in 2022, compared to $177.03 million in 2021, reflecting a decline of 40.06%[18] Assets and Liabilities - The company's total assets as of December 31, 2022, amounted to RMB 2,976,007,000, an increase from RMB 2,781,172,000 in 2021[4] - Total liabilities increased to RMB 722,986,000 in 2022 from RMB 591,582,000 in 2021, representing a rise of 22.2%[4] - The company's total liabilities reached RMB 678,689,845 in 2022, an increase of 25.9% from RMB 539,099,929 in 2021[11] - Current liabilities rose to RMB 633,102,882 in 2022, compared to RMB 482,246,500 in 2021, an increase of 31.3%[11] - The company's total equity attributable to shareholders was RMB 2,257,102,000 as of December 31, 2022, compared to RMB 2,192,946,000 in 2021, showing an increase of 2.9%[8] Cash and Cash Equivalents - Cash and cash equivalents as of December 31, 2022, were RMB 1,289,302,664, up from RMB 1,208,880,911 in 2021[6] - Cash flow from operating activities for 2022 was $165.27 million, a decrease of 38.43% from $268.90 million in 2021[21] - The company reported cash and cash equivalents at year-end 2022 of $1.29 billion, an increase from $1.21 billion at the end of 2021[23] - Cash and bank deposits as of December 31, 2022, amount to RMB 1,289,258,185, an increase from RMB 1,208,855,545 in 2021[126] Research and Development - Research and development expenses increased slightly to RMB 226,850,903 in 2022 from RMB 224,387,287 in 2021, indicating a focus on innovation[13] - Research and development expenditures are classified into research phase and development phase, with development costs capitalized only if specific criteria are met[87] - Research and development expenses for 2022 totaled RMB 233,659,132, a decrease from RMB 248,153,842 in 2021, with RMB 226,850,903 recognized in profit or loss[178] Shareholder Equity and Dividends - The company distributed RMB 72,030,000 to shareholders in 2022, compared to RMB 52,150,000 in 2021, marking an increase of approximately 38.3%[34] - The total comprehensive income for 2022 was RMB 137,272,198, down from RMB 212,380,706 in 2021, reflecting a decrease of approximately 35.3%[34] - The company reported a total shareholder equity of RMB 2,321,921,130 as of December 31, 2022, reflecting a slight increase from the previous year[34] Inventory and Receivables - The company reported a decrease in inventory to RMB 40,526,760 in 2022 from RMB 35,625,222 in 2021, which is an increase of 13.4%[6] - The total accounts receivable balance as of December 31, 2022, is CNY 569,136,087, with an expected credit loss of CNY 14,777,342[138] - Accounts receivable as of December 31, 2022, total RMB 518,749,422, down from RMB 569,136,087 in 2021, indicating a decrease of approximately 8.8%[129] - The provision for bad debts for accounts receivable decreased to RMB 12,365,732 in 2022 from RMB 14,777,342 in 2021, reflecting a reduction of about 16.3%[133] Impairment and Provisions - The total impairment provision for assets decreased to CNY 16,229,937 from CNY 17,178,928 in 2021, reflecting a reduction of approximately 5.5%[190] - The provision for inventory write-down increased by CNY 3,052,947 during the year, resulting in a total of CNY 3,247,315 as of December 31, 2022, compared to CNY 4,771,622 in 2021[190] - The provision for bad debts for other receivables was zero as of December 31, 2022, compared to CNY (925) in 2021[151] Employee Compensation - The total employee compensation payable decreased to CNY 27,761,585 in 2022 from CNY 36,493,188 in 2021, reflecting a decline of about 24.5%[197] - The provision for employee benefits, including social insurance, was CNY 2,280,771 as of December 31, 2022, compared to CNY 491,727 in 2021, indicating a significant increase in employee-related expenses[199] Accounting Policies - The financial statements for the year 2022 were approved by the board of directors on March 27, 2023[41] - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete information[44] - The accounting year runs from January 1 to December 31, aligning with the calendar year[45] Other Financial Information - The company has adopted new accounting standards and interpretations issued by the Ministry of Finance, which had no significant impact on the financial statements[120] - The corporate income tax rate applicable to the company for the year 2022 is 15%, consistent with 2021[122] - The company has not recognized any taxable income for its subsidiary Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. for the years 2021 and 2022, resulting in no income tax expense[123]
复旦张江(01349) - 2022 - 年度业绩